Irfan Qureshi, M.D.

Chief Medical Officer

Irfan is a Board-certified neurologist and physician-scientist who brings 13 years of industry and academic experience to Biohaven from Bristol-Myers Squibb and the Albert Einstein College of Medicine, including early and late stage clinical development, translational research, and patient care. At BMS, he served as clinical lead for several small molecule and biologic compounds targeting rare disease indications. Irfan propelled the BMS-986168/BIIB092 anti-tau antibody development program in Progressive Supranuclear Palsy from Phase 1 into a global registrational trial (PASSPORT Study). This innovative program was licensed from BMS to Biogen in 2017. Irfan continues to hold appointments of Clinical Assistant Professor in the Departments of Neurology and Medicine at Einstein where he conducted translational research on neurological and psychiatric disorders with an emphasis on emerging technology platforms (epigenetics, non-protein-coding RNAs, and stem cells and regenerative medicine); and also served as an investigator in clinical trials evaluating a spectrum of novel diagnostics, small molecule and biological therapeutics, and medical devices.

Irfan has a deep interest in biomedical technology innovation and has served as an advisor to early stage companies, investors, and university technology transfer offices (i.e., Einstein, Burke Research Institute, SUNY Downstate Medical Center). Prior to medical school, he was an associate at Anthem Capital Management, a venture capital firm. Irfan completed his neurology training and earned his M.D. from Einstein (Hunt Scholar). He also holds a B.S. in Biomedical Engineering from Johns Hopkins University (Goldwater Scholar). He has published more than 35 articles and book chapters, in leading journals such as Nature Reviews Neuroscience, the Proceedings of the National Academy of Sciences, and Trends in Neurosciences.